TITLE

BAYER PAYS $15 MILLION MILESTONE TO GW FOR MEDICAL CANNABIS

PUB. DATE
August 2010
SOURCE
Worldwide Biotech;Aug2010, Vol. 22 Issue 8, p5
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article offers information on a milestone payment of 15 million U.S. dollars made by Bayer to GW Pharmaceuticals. The milestone was paid in line with the British government's approval of the GW Pharmaceuticals' Sativex oromucosal spray tincture for patients with spasticity from multiple sclerosis (MS). Sales forecasts for the Sativex are projected at 180 million U.S. dollars in Europe and Canada.
ACCESSION #
52570945

 

Related Articles

  • Almirall and GW Pharmaceuticals receive approval of MS drug in Germany.  // PharmaWatch: CNS;Jul2011, Vol. 10 Issue 7, p7 

    The article reports on the regulatory approval issued for Sativex and cannabiol oromucosal spray as an add-on therapy for the treatment of moderate to severe spasticity resulting from multiple sclerosis (MS) developed by GW Pharmaceuticals PLC and marketed by Almirall SA in Germany. It notes...

  • GW Shares Take A Blow With Delay On Sativex. Moran, Nuala // BioWorld International;7/25/2007, Vol. 12 Issue 30, p1 

    The article reports on the decline in shares of GW Pharmaceuticals after its forced withdrawal to submit Sativex as treatment for spasticity in multiple sclerosis. Chief executive officer Justin Gover explains the action did not involve issues on quality or safety. Mike Barnes, president of the...

  • Positive U.S. Phase IIb Trial for GW's Sativex.  // Bioworld Week;3/29/2010, Vol. 18 Issue 13, p4 

    The article reports on GW Pharmaceuticals PLC which seeks U.S. approval for preliminary Phase IIb trial of its cannabis-based medicine Sativex in treating pain for patients with advanced cancer.

  • EUROPE TO MARKET POT FOR PAIN. Houlton, Sarah // Pharmaceutical Executive;Jul2003, Vol. 23 Issue 7, p19 

    Reports that GW Pharmaceuticals has granted exclusive rights to Bayer AG to market Sativex, a cannabis-base medicines in Great Britain. Effectiveness of Sativex in the treatment of multiple sclerosis; Reduction of neuropathic pain.

  • WHAT TO TELL YOUR PATIENTS.  // GP: General Practitioner;11/18/2002, p55 

    Focuses on the statement given by GW Pharmaceuticals PLC regarding the use of cannabis-based product for the treatment of multiple sclerosis (MS). Disadvantages of using cannabis for the treatment of MS.

  • GW Announces UK Launch of World's First Prescription Cannabis Medicine.  // Operating Theatre Journal;Jul2010, Issue 238, p8 

    The article reports on the announcement of GW Pharmaceuticals PLC regarding the Great Britain launch of Sativex(R), the first prescription cannabis-based medicine for spasticity due to multiple sclerosis (MS).

  • GW reports positive results from Phase III study of spasticity drug.  // PharmaWatch: CNS;Apr2009, Vol. 8 Issue 4, p8 

    The article reports on the positive preliminary results of the Phase III double-blind randomized placebo-controlled study for Sativex of Great Britain-based pharmaceutical company GW Pharmaceuticals PLC. An overview of the study is provided, in which Satevix is favored compared to Placebo. In...

  • IN BRIEF.  // Practice Nurse;4/29/2005, Vol. 29 Issue 8, p7 

    Presents news briefs on medical care and health services in Great Britain, as of April 2005. Findings of a survey about the value of general practice surgery; Drug approval received by GW Pharmaceuticals for its cannabis-based medicine for patients with multiple sclerosis.

  • FLOWER POWER. Potter, David // Biologist;Jun2012, Vol. 59 Issue 2, p15 

    The article offers information on the illegal drug cannabis and how it affects the human body. Cannabis is best known as an illegally grown recreational drug; the more potent upper leaves and flowers of the plant. GW Pharmaceuticals PLC grows over 1.5 million cannabis plants to produce Sativex...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics